Estradiol (E2): Normal Range by Cycle Phase, Menopause, and in Men

Reviewed by AskAnything Clinical Team, MD-reviewedLast updated 2026-04-26

An estradiol of 100 pg/mL is normal at mid-cycle, suspicious in a postmenopausal woman, and abnormal in a man. The number alone tells you almost nothing. The cycle day, the life stage, the pregnancy status, and even the assay used to measure it tell you everything.

This is the estrogen that does most of the work. Estradiol drives follicle development, builds and sheds the endometrium, protects bone, shapes mood and sleep, and figures into lipid metabolism. Estrone and estriol have niches, but estradiol is the one your fertility doctor, your menopause specialist, and your endocrinologist actually care about. It is also the estrogen that matters during HRT, gender-affirming feminizing therapy, and the flip side of any testosterone regimen, because aromatase converts testosterone to estradiol whether anyone is watching.

If you are testing estradiol, the right cycle day matters more than almost anything else. A "normal" result drawn on the wrong day of your cycle is just a number with no context.

What estradiol measures

Estradiol in premenopausal women is made primarily by granulosa cells of the developing ovarian follicle. In men and postmenopausal women, the dominant source shifts to peripheral aromatization, adipose tissue converts androgens (testosterone, androstenedione) to estradiol via the aromatase enzyme. This is why obese men and postmenopausal women on testosterone therapy can develop high estradiol levels and gynecomastia.

Two main assay platforms exist:

  • Direct immunoassay: the standard for most clinical use. Acceptable accuracy at premenopausal levels but unreliable below ~30 pg/mL. Should not be used to monitor postmenopausal women, men, children, or aromatase inhibitor therapy.
  • LC-MS/MS (mass spectrometry): the gold standard. Accurate at low levels. Order when the answer matters: men, postmenopausal monitoring, children, aromatase inhibitor monitoring.

Estradiol reference ranges

DemographicLowHighUnit
Follicular phase (women)30120pg/mL
Mid-cycle peak (women)200500pg/mL
Luteal phase (women)70250pg/mL
Postmenopausal women030pg/mL
Pregnancy, third trimester500025000pg/mL
Adult men1040pg/mL
Pre-pubertal children015pg/mL

Cycle and life-stage dependent:

  • Follicular phase (cycle days 1–13): 30–120 pg/mL. Lowest at menses, climbing as the dominant follicle matures.
  • Mid-cycle peak (around day 13–14): 200–500 pg/mL. Triggers the LH surge.
  • Luteal phase (cycle days 15–28): 70–250 pg/mL. Secondary peak from corpus luteum.
  • Menses (day 1–5): 30–100 pg/mL.
  • Postmenopausal: typically below 30 pg/mL (often below 10 on LC-MS/MS).
  • Pregnancy first trimester: 200–4000 pg/mL.
  • Pregnancy third trimester: 5000–25,000 pg/mL.
  • Adult men: 10–40 pg/mL.
  • Pre-pubertal children: below 15 pg/mL.

For fertility evaluation, the relevant test is "day 3 estradiol", drawn cycle days 2–4. Elevated day 3 estradiol (>80 pg/mL) suggests diminished ovarian reserve, with FSH artificially suppressed by the high estradiol.

What high estradiol means

Context determines whether a value is "high":

  • Reproductive-age women: high estradiol mid-cycle is normal. High estradiol in the early follicular phase suggests diminished ovarian reserve. Persistently high estradiol with irregular cycles raises concern for granulosa cell tumor.
  • Postmenopausal women: anything above ~30 pg/mL warrants explanation. Causes: HRT, obesity, ovarian or adrenal tumor, adrenal hyperplasia, exogenous estrogen exposure (creams, supplements). Also consider malignancy-related estrogen production.
  • Men: above 40–50 pg/mL is high. Causes:
    • Obesity (peripheral aromatization).
    • Testosterone replacement (aromatization of exogenous testosterone).
    • Liver disease (impaired estrogen clearance).
    • Estrogen-secreting tumor (adrenal, testicular, hepatic).
    • Anabolic steroid use.
    • Klinefelter syndrome.
  • Children: high estradiol may indicate precocious puberty or estrogen-secreting tumor.

Symptoms of estrogen excess in men include gynecomastia, decreased libido, and emotional lability. In women, persistent estrogen excess increases risk for endometrial hyperplasia and breast tissue effects.

What low estradiol means

Again, depends on context:

  • Postmenopausal women: low is expected and normal. The job of HRT, when prescribed, is to bring estradiol back into a tolerable physiologic range, not to high-normal cycling levels.
  • Reproductive-age women:
    • Hypothalamic amenorrhea (low body weight, overtraining, stress, eating disorders), low estradiol with low/normal LH and FSH.
    • Premature ovarian insufficiency, low estradiol with high FSH (typically >25), often before age 40.
    • Functional hypothalamic amenorrhea, usually reversible with restoration of nutrition and reduced stress.
    • Hyperprolactinemia, high prolactin suppresses GnRH and downstream estradiol.
    • Anorexia nervosa, severe, persistent estradiol suppression.
    • Pituitary disease.
  • Men: very low estradiol (below ~10 pg/mL) on testosterone therapy with aromatase inhibitors is increasingly recognized as harmful, with bone loss, joint pain, and decreased libido. Some estradiol is essential for male health.

The bone-protective effects of estradiol in men are well established. The trend in androgen-replacement medicine is to allow physiologic estradiol rather than suppress it.

Cycle day and timing, getting the right test

Estradiol means different things on different cycle days. For specific clinical questions:

  • Ovarian reserve / fertility evaluation: day 2–4 ("day 3"), paired with FSH and AMH.
  • Confirming ovulation timing: mid-cycle estradiol peak followed by LH surge.
  • Confirming menopause: typically not done with estradiol alone. Sustained FSH >25 with low estradiol over months in a woman with amenorrhea makes the diagnosis.
  • HRT monitoring: timing depends on formulation. Trough levels (just before next dose) for transdermal patches; mid-cycle for cyclical regimens.
  • Aromatase inhibitor monitoring: order LC-MS/MS; immunoassays are too imprecise at the suppressed levels.
  • Gender-affirming feminizing hormone therapy: typically targets premenopausal female range (100–200 pg/mL).
  • Men on testosterone replacement: periodic estradiol checks if symptomatic for high estradiol; routine universal aromatase inhibition is not recommended.

Track this biomarker over time in AskAnything.health — upload your lab results and see trends at a glance.

When to act on estradiol

  • Postmenopausal woman with estradiol above 30 pg/mL not on HRT: investigate for ovarian, adrenal, or peripheral source.
  • Man with estradiol above 50 pg/mL and symptoms (gynecomastia, low libido): evaluate for obesity, liver disease, exogenous use, or rarely tumor.
  • Reproductive-age woman with persistently low estradiol and amenorrhea: workup for hypothalamic amenorrhea (energy availability, weight, stress), prolactinoma, premature ovarian insufficiency.
  • Day 3 estradiol above 80 pg/mL: diminished ovarian reserve; FSH may look falsely normal.
  • Precocious puberty in a child: pediatric endocrinology evaluation.
  • Use LC-MS/MS, not immunoassay for any low-level estradiol question (men, postmenopause, children, AI monitoring).

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider about your lab results.

Tests that complete the picture

  • FSH: paired with estradiol on day 3 for ovarian reserve; rises in menopause and POI.
  • LH: surge triggers ovulation; elevated in PCOS and menopause.
  • Progesterone: luteal phase confirmation of ovulation.
  • AMH: better ovarian reserve marker than day 3 FSH/E2 in many cases.
  • Prolactin: workup of amenorrhea or low estradiol.
  • TSH: thyroid disease causes menstrual irregularity.
  • Total testosterone and SHBG: particularly for hyperandrogenism workup.

Patterns to recognize

Combinations of values that together point at a specific clinical picture. One number rarely tells the whole story.

Premature ovarian insufficiency / menopause

  • FSH >25 mIU/mL on two draws 4–6 weeks apart
  • Estradiol low (<30 pg/mL)
  • Amenorrhea or oligomenorrhea
  • Age <40 (POI) or age-appropriate (menopause)

The ovary has stopped responding; pituitary gonadotropins climb while estrogen falls.

Next: Bone density and cardiovascular risk assessment; consider HRT if not contraindicated.

Functional hypothalamic amenorrhea

  • Estradiol low (<30 pg/mL)
  • LH and FSH low or low-normal
  • Prolactin and TSH normal
  • Low BMI, overtraining, or chronic stress

Energy deficiency suppresses GnRH; gonadotropins and estrogen all drop together.

Next: Restore energy availability and reduce training load; bone density baseline.

Diminished ovarian reserve workup

  • Day 3 FSH >10 mIU/mL
  • Day 3 estradiol >80 pg/mL (false-suppresses FSH)
  • AMH <1 ng/mL
  • Antral follicle count low on TVUS

Day 3 estradiol must be paired with FSH or it can mask a high FSH reading.

Next: Reproductive endocrinology referral; discuss IVF timing.

Aromatase excess in men (obesity)

  • Estradiol elevated for men
  • Total testosterone low or low-normal
  • BMI elevated, fatty liver
  • Gynecomastia, low libido

Adipose aromatizes testosterone to estradiol, suppressing the HPG axis further.

Next: Weight loss, sleep apnea workup; aromatase inhibitor only in selected cases.

Hyperprolactinemia suppressing estrogen

  • Estradiol low
  • LH and FSH low or inappropriately normal
  • Prolactin elevated (>25 ng/mL, often >100)
  • Galactorrhea or visual field changes

Prolactin suppresses GnRH pulsatility; estrogen drops as a downstream effect.

Next: Pituitary MRI if prolactin persistently elevated; rule out medication causes.

Frequently Asked Questions

It depends entirely on context. Reproductive-age women cycle from ~30 pg/mL at menses to 200–500 pg/mL at the mid-cycle peak. Postmenopausal women sit below 30 pg/mL. Adult men run 10–40 pg/mL. Pregnancy reaches thousands. Always interpret against the right reference for cycle day, sex, and life stage.

Depends on the question. For fertility/ovarian reserve, draw cycle day 2–4 along with FSH. To document mid-cycle peak, days 12–14. To pair with progesterone confirming ovulation, around day 21 of a 28-day cycle.

Estradiol is necessary for male bone health, lipid metabolism, libido, and cognition, but excessively high levels cause gynecomastia, low libido, and emotional changes. Most cases of "high estradiol in men" reflect obesity, exogenous testosterone, or liver disease. Suppressing male estradiol with aromatase inhibitors is harmful in most situations.

For transdermal patches, draw a trough (just before applying a new patch). For oral or injectable formulations, timing varies. For aromatase inhibitor therapy, order LC-MS/MS, standard immunoassays are not accurate at the suppressed levels they produce.

Not by itself. Menopause is diagnosed clinically, 12 months of amenorrhea in the right age range, sometimes supported by sustained FSH above 25 mIU/mL with low estradiol. A single low estradiol does not confirm menopause; perimenopausal swings can produce briefly low values followed by normal cycles.

Possible causes include hypothalamic amenorrhea (low body weight, overtraining, stress), hyperprolactinemia, premature ovarian insufficiency, anorexia nervosa, severe chronic illness, and pituitary disease. The workup includes FSH, LH, prolactin, TSH, and a careful history of weight, exercise, and energy intake.

Drawn cycle days 2–4 alongside FSH, day 3 estradiol assesses ovarian reserve and the sensitivity of the day 3 FSH measurement. Estradiol above 80 pg/mL on day 3 can falsely suppress FSH into the normal range and signal diminished reserve in its own right.

For premenopausal women, standard immunoassay is fine. For men, postmenopausal women, children, and any patient on aromatase inhibitors, order LC-MS/MS, immunoassay is unreliable at low levels and clinical decisions can swing on the difference.

Track your lab results over time

Upload your blood work and see trends, reference ranges, and AI-powered insights — all in one place.

Get Started

Not medical advice. AskAnything.health is an AI-powered second-opinion tool designed to help you understand your health data. It does not diagnose, treat, or replace professional medical care. Always consult a qualified healthcare provider before making medical decisions. Your data is processed securely and never shared with third parties — see our Privacy Policy.